For many people, a common experience with annual checkups is: "I get screened every year, so how did it come back at a late stage?" In Japan, by contrast, the overall 5-year cancer survival rate stands at 68.9%, with detection rates for early gastrointestinal cancer among the best in the world. What exactly allows Japan to stop cancer at such an early stage? Drawing on developments from Japan's Ministry of Health, Labour and Welfare and the broader medical field, this article looks at three core technology areas behind Japan's ultra-early cancer screening.
1. Gastrointestinal Endoscopy: Not Missing Even Millimeter-Scale Warning Signs
Japan has long been a global leader in gastrointestinal (gastric and colorectal) endoscopy technology, with Japanese brands dominating much of the world's endoscope equipment market. Core technologies include:
NBI (narrow-band imaging) and magnifying endoscopy: illuminating the mucosal surface with light of a specific wavelength makes the abnormal microvasculature associated with early cancerous changes easier to observe; combined with high-resolution magnifying endoscopy, this allows lesions just a few millimeters in size to be clearly identified.
AI-assisted endoscopic diagnosis (CAD EYE): Japan has widely incorporated AI technology into endoscopic examinations, helping catch tiny polyps that the human eye might miss and reducing the rate of missed diagnoses.
Double-reading quality control: in Japan's precision health checkups (ningen dock), an imaging report is typically independently reviewed by two or more radiology specialists, and this rigorous quality-control process helps improve diagnostic accuracy. Building on this, a substantial share of early-stage gastric cancers can be cured through minimally invasive endoscopic submucosal dissection (ESD), without the need for open surgery.
2. Liquid Biopsy: Detecting Cancer Signals at the Cellular Level
Japan is at the forefront of the commercial application of biological-sample-based cancer pre-screening, with some technologies able to detect cancer-related signals at a stage before a mass would even be visible on CT or MRI imaging.
Multi-cancer microRNA screening: this technology detects microRNA in the blood, allowing simultaneous preliminary screening for several common cancers, including gastric, lung, and breast cancer.
N-NOSE nematode-based cancer screening: a distinctively Japanese technical approach that uses genetically modified nematode worms' attraction to specific odors in cancer patients' urine as a preliminary screening method — requiring only a small urine sample and relatively low in cost.
3. Focused on Asian Women: Dense Breast Tissue Screening
Asian women more commonly have "dense breast tissue," and on a traditional mammogram, both dense glandular tissue and tumors appear white — creating a "white-on-white" risk of missed diagnosis. To address this challenge, Japan's medical community has adopted a combined screening approach using 3D breast tomosynthesis (DBT) and fully automated breast ultrasound (ABUS), and is also advancing policy to inform patients of their own breast tissue density, helping women choose the screening method best suited to them.
Preventive Medicine Is the Best Gift You Can Give Your Future Self
Winning against cancer often comes down to catching it early. Japan's proactive approach to preventive medicine — built on mature hardware, AI-assisted technology, and a finely tuned checkup system tailored to Asian populations — is a direct expression of this philosophy. MIZUHO PHARMA can help connect you with Japan's leading cancer research centers, university-affiliated hospitals, and high-end precision health checkup centers, offering one-stop support including specialist booking, medical translation, and dedicated accompaniment.